11 results
Primary objective* To evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) at rest in comparison with placebo in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).Secondary objectives* To…
To demonstrate that macitentan improves exercise capacity in comparison with placebo in subjects with Eisenmenger Syndrome (ES).
1. to study the effect of spironolacton and triamterene on blood pressure in anuric hemodialysis patients.2. to study the effect of treatment on body weight, serum elektrolytes, 24-hours sodium excretion, plasma aldosterone and renin concentrations…
The main objective is to investigate the role of MRs in memory acquisition and recall during stress and non-stress conditions. Specifically, we are interested in two domains of memory, spatial and fear memory. Secondary objectives are to determine…
The primary objective of this study is to investigate the role of the MR in memory performance under stressful and non-stressful conditions in humans. More specifically the following question will be answered: What effects does the MR antagonist…
Primary: To evaluate the safety and tolerability of LY3045697 after multiple oral dosing in healthy subjectsSecondary: To investigate the pharmacokinetics of LY3045697 after multiple oral dosing in healthy subjects
Primary objectiveTo compare the effect on pulmonary vascular resistance (PVR) of an initial triple oral regimen (macitentan, tadalafil, selexipag) versus an initial dual oral regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-…
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary…
The primary objective of the SPIRIT*HF study is to compare Spironolactone to Placebo in reducing the rate…
In patients with acute MI (STEMI or Non-STEMI) who have undergone PCI, the objectives are to determine: 1. If colchicine can reduce the incidence of cardiovascular death, recurrent MI, or stroke. 2. If routine use of spironolactone can reduce the…
To determine whether VSA treatment with the novel ERA macitentan reduces the frequency and severity of anginal complaints among patients with clinically defined VSA. To determine side effects related to treatment with macitentan in patients with VSA…